STOCK TITAN
  1. Home
  2. Sec-filings
  3. BOLT
  4. [Form 4] Bolt Biotherapeutics, Inc. Insider Trading Activity

Bolt Biotherapeutics (BOLT) reports director option cancellations

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

A director of Bolt Biotherapeutics, Inc. reported multiple option transactions dated December 12, 2025 involving director stock options on Bolt common stock. The director canceled several existing stock options and received new director stock options over the same numbers of shares, with each exchange recorded as a disposal and a corresponding acquisition.

In each case, the existing option was canceled in exchange for a new option with a lower exercise price of $5.44. One new option covering 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the director’s continuous service, and will vest in full upon a change in control of Bolt Biotherapeutics.

Positive

  • None.

Negative

  • None.
Insider LAPORTE KATHLEEN
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (Right to Buy) 1,392 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,392 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,250 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,250 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,250 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,250 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,250 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,250 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,250 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,250 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,100 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,100 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,100 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,100 $0.00 --
Holdings After Transaction: Director Stock Option (Right to Buy) — 1,392 shares (Direct)
Footnotes (1)
  1. The option is fully vested and exercisable. The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAPORTE KATHLEEN
(Last) (First) (Middle)
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,392 (1) 12/28/2030 Common Stock 1,392 (2) 1,392 D
Director Stock Option (Right to Buy) $88.2 12/12/2025 D 1,392 (1) 12/28/2030 Common Stock 1,392 (2) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,250 (1) 03/23/2032 Common Stock 1,250 (3) 1,250 D
Director Stock Option (Right to Buy) $60.6 12/12/2025 D 1,250 (1) 03/23/2032 Common Stock 1,250 (3) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,250 (1) 06/09/2032 Common Stock 1,250 (4) 1,250 D
Director Stock Option (Right to Buy) $39.8 12/12/2025 D 1,250 (1) 06/09/2032 Common Stock 1,250 (4) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,250 (1) 12/13/2032 Common Stock 1,250 (5) 1,250 D
Director Stock Option (Right to Buy) $27.2 12/12/2025 D 1,250 (1) 12/13/2032 Common Stock 1,250 (5) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,250 (1) 06/11/2033 Common Stock 1,250 (6) 1,250 D
Director Stock Option (Right to Buy) $32.6 12/12/2025 D 1,250 (1) 06/11/2033 Common Stock 1,250 (6) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,100 (1) 06/11/2034 Common Stock 1,100 (7) 1,100 D
Director Stock Option (Right to Buy) $15.364 12/12/2025 D 1,100 (1) 06/11/2034 Common Stock 1,100 (7) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,100 (8) 05/26/2035 Common Stock 1,100 (9) 1,100 D
Director Stock Option (Right to Buy) $6.4 12/12/2025 D 1,100 (8) 05/26/2035 Common Stock 1,100 (9) 0 D
Explanation of Responses:
1. The option is fully vested and exercisable.
2. The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price.
3. The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price.
4. The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price.
5. The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price.
6. The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price.
7. The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price.
8. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
9. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
/s/ William P. Quinn, Attorney-in-Fact 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bolt Biotherapeutics (BOLT) report on December 12, 2025?

Bolt Biotherapeutics disclosed that a director canceled several existing stock options and received new director stock options on December 12, 2025, recorded as matching disposals and acquisitions.

How were the director's Bolt Biotherapeutics (BOLT) stock options changed?

The director agreed to cancel existing options granted on multiple prior dates in exchange for new options over the same number of shares, each with a lower exercise price.

What is the exercise price of the new Bolt Biotherapeutics (BOLT) director stock options?

Each new director stock option reported has an exercise price of $5.44, which is described as lower than the exercise price of the corresponding canceled option.

When do the new Bolt Biotherapeutics (BOLT) stock options expire?

The new director stock options have expiration dates ranging from December 28, 2030 to May 26, 2035, depending on the specific grant.

What are the vesting terms for the 1,100-share Bolt Biotherapeutics (BOLT) option grant?

The 1,100-share option marked with footnote (8) will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to continuous service, and will vest in full upon a change in control of Bolt Biotherapeutics.

Does the filing indicate why prior Bolt Biotherapeutics (BOLT) options were canceled?

Yes. The explanations state that the director agreed to cancellation of options granted on several prior dates in exchange for new options having a lower exercise price.